Computational Modeling Toward Understanding Agonist Binding on Dopamine 3

The dopamine 3 (D3) receptor is a promising therapeutic target for the treatment of nervous system disorders, such as Parkinson's disease, and current research interests primarily focus on the discovery/design of potent D3 agonists. Herein, a well-designed computational protocol, which combines pharmacophore identification, homology modeling, molecular docking, and molecular dynamics (MD) simulations, was employed to understand the agonist binding on D3 aiming to provide insights into the development of novel potent D3 agonists. We (1) identified the chemical features required in effective D3 agonists by pharmacophore modeling based upon 18 known diverse D3 agonists; (2) constructed the three-dimensional (3D) structure of D3 based on homology modeling and the pharmacophore hypothesis; (3) identified the binding modes of the agonists to D3 by the correlation between the predicted binding free energies and the experimental values; and (4) investigated the induced fit of D3 upon agonist binding through MD simulations. The pharmacophore models of the D3 agonists and the 3D structure of D3 can be used for either ligand- or receptor-based drug design. Furthermore, the MD simulations further give the insight that the long and flexible EL2 acts as a "door" for agonist binding, and the "ionic lock" at the bottom of TM3 and TM6 is essential to transduce the activation signal.

[1]  R. Stevens,et al.  High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. , 2007, Science.

[2]  J. A. Javitch,et al.  448. Differentiating dopamine D2 ligands by their sensitivities to modification of Cys118 , 1996, Biological Psychiatry.

[3]  Zhihai Liu,et al.  Comparative Assessment of Scoring Functions on a Diverse Test Set , 2009, J. Chem. Inf. Model..

[4]  J. Javitch,et al.  Residues in the fifth membrane-spanning segment of the dopamine D2 receptor exposed in the binding-site crevice. , 1995, Biochemistry.

[5]  P. Strange,et al.  Role of Conserved Serine Residues in the Interaction of Agonists with D3 Dopamine Receptors , 1999, Journal of neurochemistry.

[6]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997, J. Comput. Chem..

[7]  H. Akil,et al.  Hydrophobic Residues of the D2 Dopamine Receptor Are Important for Binding and Signal Transduction , 1995, Journal of neurochemistry.

[8]  Andrew Smellie,et al.  Poling: Promoting conformational variation , 1995, J. Comput. Chem..

[9]  J. Joyce,et al.  Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[11]  J. Ballesteros,et al.  The first transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle. , 2000, Biochemistry.

[12]  Weiliang Zhu,et al.  Dopamine D1 receptor agonist and D2 receptor antagonist effects of the natural product (-)-stepholidine: molecular modeling and dynamics simulations. , 2007, Biophysical journal.

[13]  Harald Hübner,et al.  Fancy bioisosteres: synthesis and dopaminergic properties of the endiyne FAUC 88 as a novel non-aromatic D3 agonist. , 2005, Bioorganic & medicinal chemistry.

[14]  Shaomeng Wang,et al.  Computational elucidation of the structural basis of ligand binding to the dopamine 3 receptor through docking and homology modeling. , 2006, Journal of medicinal chemistry.

[15]  Gert Vriend,et al.  A common motif in G-protein-coupled seven transmembrane helix receptors , 1993, J. Comput. Aided Mol. Des..

[16]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[17]  J. Ballesteros,et al.  A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice. , 1998, Biochemistry.

[18]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[19]  Jonathan A Javitch,et al.  Mapping the binding-site crevice of the dopamine D2 receptor by the substituted-cysteine accessibility method , 1995, Neuron.

[20]  Bruno Giros,et al.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.

[21]  J. Ballesteros,et al.  Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: contributions of the second membrane-spanning segment. , 1999, Biochemistry.

[22]  Xueliang Fang,et al.  Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. , 2003, Journal of medicinal chemistry.

[23]  Jian Zhang,et al.  Design, synthesis, and evaluation of potent and selective ligands for the dopamine 3 (D3) receptor with a novel in vivo behavioral profile. , 2008, Journal of medicinal chemistry.

[24]  K. Svensson,et al.  Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 2. Effects of 8-amino nitrogen substitution on serotonin receptor binding and pharmacology. , 1995, Journal of medicinal chemistry.

[25]  Peter Gmeiner,et al.  The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects. , 2006, Pharmacology & therapeutics.

[26]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[27]  Manfred Burghammer,et al.  Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. , 2007, Nature.

[28]  Roman G. Efremov,et al.  A Solvent Model for Simulations of Peptides in Bilayers. II. Membrane-Spanning α-Helices , 1999 .

[29]  Mario Tiberi,et al.  Delineation of the Structural Basis for the Activation Properties of the Dopamine D1 Receptor Subtypes* , 1999, The Journal of Biological Chemistry.

[30]  Harald Hübner,et al.  Practical ex-chiral-pool methodology for the synthesis of dopaminergic tetrahydroindoles , 2004 .

[31]  Harald Hübner,et al.  Analogues of FAUC 73 revealing new insights into the structural requirements of nonaromatic dopamine D3 receptor agonists. , 2004, Bioorganic & medicinal chemistry.

[32]  L. W. Cooke,et al.  Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. , 1995, The Journal of pharmacology and experimental therapeutics.

[33]  D. M. F. Aalten,et al.  PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules , 1996, J. Comput. Aided Mol. Des..

[34]  J. Ballesteros,et al.  Activation of the β2-Adrenergic Receptor Involves Disruption of an Ionic Lock between the Cytoplasmic Ends of Transmembrane Segments 3 and 6* , 2001, The Journal of Biological Chemistry.

[35]  M. Millan,et al.  Dopamine D3 receptor agonists for protection and repair in Parkinson's disease. , 2007, Current opinion in pharmacology.

[36]  Thierry Langer,et al.  Influenza Virus Neuraminidase Inhibitors: Generation and Comparison of Structure‐Based and Common Feature Pharmacophore Hypotheses and Their Application in Virtual Screening. , 2004 .

[37]  L. Naylor,et al.  Site-directed mutagenesis of Tyr417 in the rat D2 dopamine receptor. , 1994, Biochemical Society transactions.

[38]  J. Palacios,et al.  High resolution separation methods for the determination of intact human erythropoiesis stimulating agents. A review. , 2012, Analytica chimica acta.

[39]  Bruno Giros,et al.  Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA , 1991, Brain Research.

[40]  Luhua Lai,et al.  Further development and validation of empirical scoring functions for structure-based binding affinity prediction , 2002, J. Comput. Aided Mol. Des..

[41]  C. Breneman,et al.  Determining atom‐centered monopoles from molecular electrostatic potentials. The need for high sampling density in formamide conformational analysis , 1990 .

[42]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2000, Science.

[43]  Vincenzo Tortorella,et al.  Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D(3) receptor ligands. , 2002, Journal of medicinal chemistry.

[44]  H Weinstein,et al.  The fourth transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle. , 2000, Biochemistry.

[45]  H. Akil,et al.  Site-directed mutagenesis of the human dopamine D2 receptor. , 1992, European journal of pharmacology.

[46]  K. Schulten,et al.  Molecular dynamics simulation of a bilayer of 200 lipids in the gel and in the liquid crystal phase , 1993 .

[47]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[48]  Javier González-Maeso,et al.  Agonist-trafficking and hallucinogens. , 2009, Current medicinal chemistry.

[49]  H. Wikström,et al.  Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand. , 1993, European journal of pharmacology.

[50]  D. Donnelly-roberts,et al.  Central Mechanisms Regulating Penile Erection in Conscious Rats: The Dopaminergic Systems Related to the Proerectile Effect of Apomorphine , 2004, Journal of Pharmacology and Experimental Therapeutics.

[51]  J. Javitch,et al.  Differentiating dopamine D2 ligands by their sensitivities to modification of the cysteine exposed in the binding-site crevice. , 1996, Molecular pharmacology.

[52]  Peter Gmeiner,et al.  Dopamine D3 receptor ligands: recent advances in the control of subtype selectivity and intrinsic activity. , 2007, Biochimica et biophysica acta.

[53]  C Dacquet,et al.  Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. , 1995, The Journal of pharmacology and experimental therapeutics.

[54]  K. O’Malley,et al.  Characterization of a chimeric human dopamine D3/D2 receptor functionally coupled to adenylyl cyclase in Chinese hamster ovary cells. , 1995, Molecular pharmacology.

[55]  Glen L Alberts,et al.  Contributions of cysteine 114 of the human D3 dopamine receptor to ligand binding and sensitivity to external oxidizing agents , 1998, British journal of pharmacology.

[56]  M. P. Turpin,et al.  Mapping of dopamine D3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki Forest virus system. , 1998, Journal of receptor and signal transduction research.

[57]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[58]  T. Heffner,et al.  Studies of the active conformation of a novel series of benzamide dopamine D2 agonists. , 1994, Journal of medicinal chemistry.

[59]  Harald Hübner,et al.  Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists. , 2002, Journal of medicinal chemistry.

[60]  P. Gmeiner,et al.  Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D(3) subtype. , 2000, Journal of medicinal chemistry.

[61]  D. van der Spoel,et al.  GROMACS: A message-passing parallel molecular dynamics implementation , 1995 .

[62]  J. Hagan,et al.  Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat. , 2000, Journal of medicinal chemistry.

[63]  D. Lévesque,et al.  Effects of reciprocal chimeras between the C‐terminal portion of third intracellular loops of the human dopamine D2 and D3 receptors , 1999, FEBS letters.

[64]  M. Burghammer,et al.  Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.